FLUOROPHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.fluoropharma.com
BFPET for Regional Myocardial Perfusion Imaging
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Fluoropharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02252783
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: CardioPET™
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Fluoropharma, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01826773
- Locations
- 🇧🇪
Dienst Nucleaire Geneeskunde, OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪Nucleaire Geneesunde Gasthuisberg Leuven Hospital, Leuven, Belgium
🇧🇪Service de Medicine Nucleaire, Centre Hospitalier Univerisataire de Liege, Belgium, Liege, Belgium
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Fluoropharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00733460
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Fluoropharma, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00413647
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath